ArticleBiological procedures online2025
DKK1 Overexpression in Lung Adenocarcinoma: Prognostic Implications, Immune Microenvironment Correlates, and Regulatory Network Characterization.
Article in Biological procedures online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) is a prevalent malignancy with poor survival outcomes, underscoring the need for better biomarkers and therapeutic targets. Dickkopf-1 (DKK1), a secreted Wnt pathway inhibitor, is dysregulated in many cancers and can promote tumor progression and immune evasion. This study aimed to investigate DKK1 expression and its clinical, immunological, and molecular significance in LUAD.
methodsTranscriptomic and clinical data from TCGA and GTEx were analyzed to evaluate DKK1 expression, prognostic relevance, immune infiltration, and associated pathways. Functional enrichment and co-expression networks were constructed in silico. Key findings were validated in vitro using siRNA-mediated DKK1 knockdown in lung cancer cells, followed by assays of proliferation, migration/invasion, apoptosis, cell cycle, and protein expression.
resultsDKK1 was significantly overexpressed in LUAD and correlated with advanced stage and poor survival. Enrichment analyses suggested roles in extracellular matrix remodeling and invasion. High DKK1 expression was also associated with increased infiltration of innate immune cells and elevated PD-L1 expression, indicating a potential role in shaping an immunosuppressive microenvironment. Functional experiments further confirmed that DKK1 knockdown reduced proliferation, impaired migration and invasion, induced cell-cycle arrest, and promoted apoptosis in LUAD cells.
conclusionsDKK1 serves as a strong prognostic biomarker in LUAD, linking high expression to aggressive clinicopathologic features and immunosuppressive microenvironments. Its knockdown reversed malignant phenotypes in vitro, supporting DKK1 as a potential therapeutic target and a predictor of immunotherapy resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.